CN Patent

CN102037008B — 蛋白酶稳定化的、酰化胰岛素类似物

Assigned to Novo Nordisk AS · Expires 2016-08-31 · 10y expired

What this patent protects

对蛋白酶表现出抗性的新型酰化胰岛素类似物可有效地通过肺部或口服给药。该胰岛素类似物包含B25H和A14E或A14H。

USPTO Abstract

对蛋白酶表现出抗性的新型酰化胰岛素类似物可有效地通过肺部或口服给药。该胰岛素类似物包含B25H和A14E或A14H。

Drugs covered by this patent

Patent Metadata

Patent number
CN102037008B
Jurisdiction
CN
Classification
—
Expires
2016-08-31
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.